Forum pracy nad projektem wskrzeszenia The Forge

[xp052505]

Review of best practices to shorten time


Physical development of this direction is still a long way to go. One important question is, heavy Multinational companies in China want to integrate China into its global development plans. However, including China's current regulations, review the resources and time,[link widoczny dla zalogowanych], and foreign companies own a variety of reasons,[link widoczny dla zalogowanych], China's participation in global clinical trials,[link widoczny dla zalogowanych], are still lower than South Korea and China Taiwan. Meanwhile, China's participation in a large extent limited to clinical practice range surface. How the introduction of foreign clinical development capabilities, the country must face the problem. State Food and Drug Administration this up at the meeting Secretary Zhang made a very unique perspective. He did not evade the time limit for approval of clinical trials in China, the phenomenon is too long, but that only by continuing to pursue the Comment registration management system in order to shorten the time limit for approval of clinical trials, and this Drug agencies in the past been developed for the pharmaceutical industry, some out of international norms (. Zhang also pointed out that global drug development is also a challenge to the pharmaceutical companies. With the drug regulatory and review of emerging market institutions the ability to continuously improve the technical review, requiring pharmaceutical companies, especially multinational pharmaceutical companies in emerging markets not just as a base for clinical trials, should also focus on the local drug registration staff scientific ability and good communication ability. Global drug development not only to drug regulatory agencies in emerging market challenges, but also to the drug regulatory bodies in mature markets challenges. As more clinical trial data from the emerging markets, mature markets regulators will face in emerging markets with the same problem drug regulatory agencies is how to use from other countries or regions collected clinical data to support their the listing application. This is also brought to the mature markets of China SFDA drug regulatory agencies in advance to think about. I (Dr. Li Zili also contributed to the article) 23} {focus on Chinese medicine research management norms in the industry of self-discipline and normative work. (See Yu-country magazine site prescription drugs,[link widoczny dla zalogowanych], CRO Medical Technology Market Association of the Commonwealth Address: South Second Ring Road, Fengtai District, Beijing, No. 2O in 5465 with the research Zip: 100075 Tel: +861087632546 Mobile phone: 13521134538Emaihcrounion @ yeahcorn Contact: Zhao Jie Deng flourishing Guangzhou Office: prescription drugs September 1993. is registered by the Ministry of Civil Affairs.; a legal personality of the industry, social organizations (hereinafter referred to as the growth. hope that more scientific research, production companies and related industries to become our member companies. We will I; past dedication to member services. bully with the development and progress. Association members must pay membership dues regularly. dues j 3,[link widoczny dla zalogowanych],000 yuan per year. Please Member registration form. to facilitate contact and information delivery. Unit Name Address legal representative (responsible person) contact person and contact phone e-mail in which (E-ma at PC DATE (seal) Account name: National Association of Medical Technology Market Account Bank: China Construction Bank, Beijing Exhibition Road Branch Account number: 11 �� 1O16700056021928 Address: North Lishi Road, Xicheng District, Beijing, Kim Tae-101 Room 1206, Tung Wah Hotel: 1O �� 44 Tel: O1O-68311506O1O-88377790
More articles related to topics：


tory burch reva Accreditation to undertake the fun

[link widoczny dla zalogowanych]

uggs kopen Language courses from the development t